Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: Migaldendranib in Healthy Volunteers Trial completed Ashvattha Therapeutics, Inc.Phase 1 NCT07370155
  2. Minor: Eloralintide (LY3841136) · Renal Impairment and in Participants With Normal Renal Function Trial completed Eli Lilly and CompanyPhase 1 NCT07426380
  3. Minor: Real-World Study of a Calcium Sodium Phosphosilicate Anti-Sensitivity Toothpaste for Dentin Hypersensitivity Relief Trial completed HALEONNot applicable NCT07300540
  4. Minor: DOT Spectacles in Chinese Children Extension Enrollment closed, study ongoing SightGlass Vision, Inc.Not applicable NCT07008001
  5. Minor: Collection of Blood Samples for New Diagnostic Devices 2 Trial completed LumiraDx UK LimitedNot specified NCT05568966
  6. Minor: Korean Post-marketing Surveillance for Xeljanz XR Trial completed PfizerNot specified NCT04876781
  7. Minor: Activia Kefir Consumption in Real-world Setting Enrollment closed, study ongoing Danone Global Research & Innovation CenterNot specified NCT07790666
  8. Minor: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing Enrollment closed, study ongoing A2 Biotherapeutics Inc.Not specified NCT04981119
  9. Minor: Specific Gait Patterns · Multiple Sclerosis Trial completed SYSNAVNot specified NCT07388992
  10. Minor: Etrasimod · Moderate to Severe Ulcerative Colitis Enrollment closed, study ongoing PfizerNot specified NCT06398626
  11. Minor: Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease Trial completed AbbVieNot specified NCT06937034
  12. Minor: Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea Enrollment closed, study ongoing Novartis PharmaceuticalsNot specified NCT05703516
  13. Minor: Iovera®° System · Upper Extremity Spasticity Trial completed Pacira Pharmaceuticals, IncNot applicable NCT06340451
  14. Minor: SPN-812 (Viloxazine Extended-release Capsule) Primary and study completion pushed from Sep 2026 to Dec 2026 Supernus Pharmaceuticals, Inc.Phase 3 NCT02736656
  15. Minor: Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy Enrollment closed, study ongoing Masahisa KatsunoPhase 2/3 NCT06862596
  16. Minor: AZA+Lus VS AZA Monotherapy in HR-MDS Completed without a posted recruiting period Peking Union Medical College HospitalPhase 3 NCT06927232
  17. Minor: Recurrent Breast Cancer and Repeated Radiation Therapy Enrollment closed, study ongoing Turku University HospitalNot applicable NCT06704659
  18. Minor: Surgical Approach in Hemiarthroplasty. A Randomized Clinical Trial Comparing Posterior and Anterior Approach Trial completed Sorlandet Hospital HFNot applicable NCT04900506
  19. Minor: 18F-mFBG Imaging for Myocardial Sympathetic Innervation Primary completion pushed from Oct 30, 2026 to Mar 30, 2027 Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Phase 2 NCT06965621
  20. Minor: 18F-mFBG Cardiac Uptake With Lewy Body Dementia Primary completion pushed from Oct 30, 2026 to Mar 30, 2027 Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Phase 2 NCT07176286
  21. Minor: Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax Enrollment closed, study ongoing National Heart, Lung, and Blood Institute (NHLBI)Not specified NCT05724121
  22. Minor: Biodistribution of [177Lu]Lu-ABY-271 · HER2-positive Metastatic Breast Cancer Primary completion pushed from Jan 1, 2027 to Jun 1, 2027 AffibodyPhase 1 NCT07081555
  23. Minor: LY4057996 in Healthy Participants and · Type 1 and Type 2 Diabetes Primary and study completion pushed from Mar 2027 to Jul 2027 Eli Lilly and CompanyPhase 1 NCT06945406
  24. Minor: Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity Enrollment closed, study ongoing British Columbia Cancer AgencyPhase 2 NCT04273061
  25. Minor: Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial) Trial completed Hellenic Institute for the Study of SepsisPhase 2 NCT06694701